Cortisone Acetate: 296 Clinical Trials, Page 23 of 30

Hide Studies Not Open or Pending

226

Parsaclisib With or Without Polatuzumab Vedotin Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma

Condition(s):Ann Arbor Stage II Diffuse Large B-Cell Lymphoma; Ann Arbor Stage II Follicular Lymphoma; Ann Arbor Stage II Marginal Zone Lymphoma; Ann Arbor Stage III Diffuse Large B-Cell Lymphoma; Ann Arbor Stage III Follicular Lymphoma; Ann Arbor Stage III Marginal Zone Lymphoma; Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma; Ann Arbor Stage IV Follicular Lymphoma; Ann Arbor Stage IV Marginal Zone Lymphoma; Diffuse Large B-Cell Lymphoma; High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements; High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements; High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements; Indolent Non-Hodgkin LymphomaLast Updated:October 30, 2023Active, not recruiting

228

Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin’s Lymphoma

Condition(s):Aggressive Non-Hodgkin Lymphoma; Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma; Ann Arbor Stage II B-Cell Non-Hodgkin Lymphoma; Ann Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma; Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma; Ann Arbor Stage III Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma; Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma; Ann Arbor Stage IV Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma; Diffuse Large B-Cell Lymphoma; High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements; High Grade B-Cell Lymphoma, Not Otherwise Specified; Indolent Non-Hodgkin Lymphoma; Mediastinal B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma; Transformed Non-Hodgkin LymphomaLast Updated:October 31, 2023Active, not recruiting

230

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas

Condition(s):Diffuse Large B-Cell Lymphoma; Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; Double-Expressor Lymphoma; EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements; High Grade B-Cell Lymphoma, Not Otherwise Specified; Neoplastic Cells With Double Expression of MYC and BCL2 Proteins Present; Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell LymphomaLast Updated:March 6, 2024Active, not recruiting

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.